EO-2463
- Generic Name
- EO-2463
A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma
Phase 1
Recruiting
- Conditions
- Follicular LymphomaMarginal Zone Lymphoma
- Interventions
- First Posted Date
- 2020-12-16
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Enterome
- Target Recruit Count
- 60
- Registration Number
- NCT04669171
- Locations
- 🇫🇷
CHU d'Amiens-Picardie - Hopital SUD, Amiens, France
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath